Pathological angiogenesis: mechanisms and therapeutic strategies
AC Dudley, AW Griffioen - Angiogenesis, 2023 - Springer
In multicellular organisms, angiogenesis, the formation of new blood vessels from pre-
existing ones, is an essential process for growth and development. Different mechanisms …
existing ones, is an essential process for growth and development. Different mechanisms …
Anti-angiogenic agents—overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
ZR Huinen, EJM Huijbers, JR van Beijnum… - Nature Reviews …, 2021 - nature.com
Immune checkpoint inhibitors have revolutionized medical oncology, although currently only
a subset of patients has a response to such treatment. A compelling body of evidence …
a subset of patients has a response to such treatment. A compelling body of evidence …
Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma
L Nayak, AM Molinaro, K Peters, JL Clarke… - Clinical Cancer …, 2021 - AACR
Purpose: VEGF is upregulated in glioblastoma and may contribute to immunosuppression.
We performed a phase II study of pembrolizumab alone or with bevacizumab in recurrent …
We performed a phase II study of pembrolizumab alone or with bevacizumab in recurrent …
[HTML][HTML] Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers
Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …
Tumor microenvironment dynamics in clear-cell renal cell carcinoma
Renal cell carcinoma stands out as one of the most immune-infiltrated tumors in pan-cancer
comparisons. Features of the tumor microenvironment heavily affect disease biology and …
comparisons. Features of the tumor microenvironment heavily affect disease biology and …
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Immunotherapies have revolutionized medical oncology following the remarkable and, in
some cases, unprecedented outcomes observed in certain groups of patients with cancer …
some cases, unprecedented outcomes observed in certain groups of patients with cancer …
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Inhibitors of VEGF (vascular endothelial growth factor)/VEGFR2 (vascular endothelial growth
factor receptor 2) are commonly used in the clinic, but their beneficial effects are only …
factor receptor 2) are commonly used in the clinic, but their beneficial effects are only …
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
RR Ramjiawan, AW Griffioen, DG Duda - Angiogenesis, 2017 - Springer
Angiogenesis is defined as the formation of new blood vessels from preexisting vessels and
has been characterized as an essential process for tumor cell proliferation and viability. This …
has been characterized as an essential process for tumor cell proliferation and viability. This …
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
M Schmittnaegel, N Rigamonti, E Kadioglu… - Science translational …, 2017 - science.org
Pathological angiogenesis is a hallmark of cancer and a therapeutic target. Vascular
endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2; also known as ANG2) …
endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2; also known as ANG2) …
First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis
Context There have been substantial changes in the management of patients with metastatic
renal cell carcinoma (mRCC) over the past decade, with upfront immunotherapy-based …
renal cell carcinoma (mRCC) over the past decade, with upfront immunotherapy-based …